The MIT/Mayo PS-OC will use pilot and trans-network projects as a mechanism to expand our understanding of therapeutic drug delivery into tumors and as a tool to enhance collaborative efforts between MIT/Mayo PS-OC investigators and with other PS-OCs. As detailed above, we will use the annual symposium and visiting seminar series as a mechanism to bring together cancer biology and physical science investigators with complimentary expertise with an overt goal of facilitating collaborative Pilot project applications. The RFA for projects will be issued prior to the annual symposium, and the Center leadership also will email members across the PS-ON to solicit a broad spectrum of studies that fit within the theme of how drug distribution influences biology. Pilot and trans-PS-OC grant proposal review and prioritization will focus on three key criteria. First, how well does the proposal fit within the broad physical sciences framework of understanding issues surrounding novel therapeutic delivery? Second, will the project likely facilitate development of meaningful collaborations between cancer biologists and physical scientists / engineers? Third, if applicable, does the project optimally use the relevant Shared Resource Cores? An initial written review of applications will be solicited from relevant experts, and the administrative core will evaluate these critiques. One of the expectations for Pilotand Trans-PS-OC projects is that funded investigators would participate in the MIT/Mayo PS-OC teleconferences and semi-annual meetings with the idea that these interactions can facilitate further collaborations within our PS-OC and across the PS-ON.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA210180-05
Application #
9994245
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2016-08-29
Project End
2021-07-31
Budget Start
2020-08-01
Budget End
2021-07-31
Support Year
5
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Massachusetts Institute of Technology
Department
Type
DUNS #
001425594
City
Cambridge
State
MA
Country
United States
Zip Code
02142
Basu, Sankha S; Randall, Elizabeth C; Regan, Michael S et al. (2018) In Vitro Liquid Extraction Surface Analysis Mass Spectrometry (ivLESA-MS) for Direct Metabolic Analysis of Adherent Cells in Culture. Anal Chem 90:4987-4991
Randall, Elizabeth C; Emdal, Kristina B; Laramy, Janice K et al. (2018) Integrated mapping of pharmacokinetics and pharmacodynamics in a patient-derived xenograft model of glioblastoma. Nat Commun 9:4904
Roos, Alison; Dhruv, Harshil D; Peng, Sen et al. (2018) EGFRvIII-Stat5 Signaling Enhances Glioblastoma Cell Migration and Survival. Mol Cancer Res 16:1185-1195
Rothenberg, Daniel A; Taliaferro, J Matthew; Huber, Sabrina M et al. (2018) A Proteomics Approach to Profiling the Temporal Translational Response to Stress and Growth. iScience 9:367-381
Prahl, Louis S; Bangasser, Patrick F; Stopfer, Lauren E et al. (2018) Microtubule-Based Control of Motor-Clutch System Mechanics in Glioma Cell Migration. Cell Rep 25:2591-2604.e8
Kim, Minjee; Ma, Daniel J; Calligaris, David et al. (2018) Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood-Brain Barrier. Mol Cancer Ther 17:1893-1901
Laramy, Janice K; Kim, Minjee; Gupta, Shiv K et al. (2017) Heterogeneous Binding and Central Nervous System Distribution of the Multitargeted Kinase Inhibitor Ponatinib Restrict Orthotopic Efficacy in a Patient-Derived Xenograft Model of Glioblastoma. J Pharmacol Exp Ther 363:136-147
Emdal, Kristina B; Dittmann, Antje; Reddy, Raven J et al. (2017) Characterization of In Vivo Resistance to Osimertinib and JNJ-61186372, an EGFR/Met Bispecific Antibody, Reveals Unique and Consensus Mechanisms of Resistance. Mol Cancer Ther 16:2572-2585
Gampa, Gautham; Vaidhyanathan, Shruthi; Sarkaria, Jann N et al. (2017) Drug delivery to melanoma brain metastases: Can current challenges lead to new opportunities? Pharmacol Res 123:10-25